PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25769431-7 2015 TNF-alpha-mediated up-regulation of placental fractalkine was reversed in the presence of the aspirin-derivative salicylate, which impaired activation of NF-kappaB p65 in TNF-alpha-treated explants. Salicylates 113-123 nuclear factor kappa B subunit 1 Homo sapiens 154-163 7890420-8 1995 Although this binding was inhibited in salicylate-treated cells, as was binding of NF-kappa B, the pattern of binding was found to differ from that noted for NF-kappa B. Salicylates 39-49 nuclear factor kappa B subunit 1 Homo sapiens 83-93 7534663-2 1995 Since salicylates have been reported to inhibit NF-kappa B activation by preventing the degradation of its inhibitor I kappa B, we studied a potential inhibition of this pathway by acetylsalicylate (aspirin) in human umbilical vein endothelial cells (HUVECs). Salicylates 6-17 nuclear factor kappa B subunit 1 Homo sapiens 48-58 21615775-14 2011 Antioxidants such as acetylcysteine and salicylate might be beneficial through free radical scavenging, anti-inflammatory and NF-kappaB inhibitory actions. Salicylates 40-50 nuclear factor kappa B subunit 1 Homo sapiens 126-135 25126374-6 2014 Salsalate belongs to the salicylate drug class, which has been shown to inhibit I-kappaB kinase, thereby inhibiting the nuclear factor-kappaB (NF-kappaB) cascade and decreasing the production of inflammatory cytokines, as well as decreasing insulin resistance. Salicylates 25-35 nuclear factor kappa B subunit 1 Homo sapiens 120-141 25126374-6 2014 Salsalate belongs to the salicylate drug class, which has been shown to inhibit I-kappaB kinase, thereby inhibiting the nuclear factor-kappaB (NF-kappaB) cascade and decreasing the production of inflammatory cytokines, as well as decreasing insulin resistance. Salicylates 25-35 nuclear factor kappa B subunit 1 Homo sapiens 143-152 25126374-7 2014 Recent short-term clinical trials have shown that 3 g to 4.5 g of salicylate therapy daily has the ability to lower insulin resistance and to reduce the levels of glucose, triglycerides, and free fatty acid concentrations through regulation of the I-kappaB kinase beta/NF-kappaB pathway, with few if any side effects. Salicylates 66-76 nuclear factor kappa B subunit 1 Homo sapiens 269-278 20298761-8 2010 Eight genes showed a biologically relevant change (P<0.05, > or =2 fold change) after 3 h treatment with salicylate; seven genes (Tp53, Birc3, Tnfrsf5, Casp7, Nfkb1, Fas, Lta, Tnfsf10) were upregulated and one gene (Pycard) was downregulated. Salicylates 111-121 nuclear factor kappa B subunit 1 Homo sapiens 165-170 20080359-6 2010 Hence, it is proposed that salicylate may have practical utility in the prevention or management of a wide range of vascular disorders as well as of metabolic syndrome and diabetes; its efficacy in these regards would likely be complemented by effective antioxidant measures, which would lessen the stimulus to NF-kappaB activation while providing benefits independent of NF-kappaB activity. Salicylates 27-37 nuclear factor kappa B subunit 1 Homo sapiens 311-320 20080359-6 2010 Hence, it is proposed that salicylate may have practical utility in the prevention or management of a wide range of vascular disorders as well as of metabolic syndrome and diabetes; its efficacy in these regards would likely be complemented by effective antioxidant measures, which would lessen the stimulus to NF-kappaB activation while providing benefits independent of NF-kappaB activity. Salicylates 27-37 nuclear factor kappa B subunit 1 Homo sapiens 372-381 16624973-11 2006 In summary, our study introduces HO-1 as novel NF-kappaB-independent anti-inflammatory target of salicylate in human endothelial cells. Salicylates 97-107 nuclear factor kappa B subunit 1 Homo sapiens 47-56 19766270-10 2010 Inhibiting NFkappaB activation with salicylate reduces IL-10 expression and the association of PGC-1alpha with p50-NFkappaB. Salicylates 36-46 nuclear factor kappa B subunit 1 Homo sapiens 11-19 19766270-10 2010 Inhibiting NFkappaB activation with salicylate reduces IL-10 expression and the association of PGC-1alpha with p50-NFkappaB. Salicylates 36-46 nuclear factor kappa B subunit 1 Homo sapiens 111-114 19766270-10 2010 Inhibiting NFkappaB activation with salicylate reduces IL-10 expression and the association of PGC-1alpha with p50-NFkappaB. Salicylates 36-46 nuclear factor kappa B subunit 1 Homo sapiens 115-123 17646662-0 2007 Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Salicylates 98-108 nuclear factor kappa B subunit 1 Homo sapiens 9-18 16624973-2 2006 Inhibition of the transcription factor nuclear factor-kappaB (NF-kappaB) has been discussed to play a role in the anti-inflammatory profile of salicylate. Salicylates 143-153 nuclear factor kappa B subunit 1 Homo sapiens 39-60 17132819-6 2007 Using high performance liquid chromatography analysis, we demonstrate that >0.5 mM salicylate levels are achievable in xenografted tumours after low-dose aspirin (40 mg/kg) treatment and that these levels, which are pharmacologically relevant to humans, are sufficient to stimulate an NF-kappaB and apoptotic response. Salicylates 86-96 nuclear factor kappa B subunit 1 Homo sapiens 288-297 16880431-0 2006 Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy. Salicylates 31-42 nuclear factor kappa B subunit 1 Homo sapiens 59-68 16792771-4 2006 In cell-based assays, salicylate can prevent NF-kappaB activation caused by loss of the cylindromatosis gene, suggesting that salicylic acid application might be a potential treatment for cylindromatosis. Salicylates 22-32 nuclear factor kappa B subunit 1 Homo sapiens 45-54 16624973-2 2006 Inhibition of the transcription factor nuclear factor-kappaB (NF-kappaB) has been discussed to play a role in the anti-inflammatory profile of salicylate. Salicylates 143-153 nuclear factor kappa B subunit 1 Homo sapiens 62-71 12664642-0 2002 Non-prostaglandin effects of aspirin III and salicylate: inhibition of integrin-dependent human neutrophil aggregation and inflammation in COX 2- and NF kappa B (P105)-knockout mice. Salicylates 45-55 nuclear factor kappa B subunit 1 Homo sapiens 162-166 16624973-3 2006 However, NF-kappaB-independent effects of salicylate have been assumed but have up to now been poorly investigated. Salicylates 42-52 nuclear factor kappa B subunit 1 Homo sapiens 9-18 16624973-4 2006 Therefore, the aim of the present study was to investigate NF-kappaB-independent anti-inflammatory mechanisms of salicylate in human umbilical vein endothelial cells using interleukin-4 (IL-4) as NF-kappaB-independent proinflammatory stimulus and P-selectin as inflammatory read-out parameter. Salicylates 113-123 nuclear factor kappa B subunit 1 Homo sapiens 59-68 16620022-7 2006 Molecular biological techniques have revealed, that many of the established conventional antiinflammatory drugs such as salicylic acids, steroids or immunuosuppressants act at the same molecules that are the target for modern biologicals, i.e., the cytokine TNF or the transcription factor NFkappaB. Salicylates 120-135 nuclear factor kappa B subunit 1 Homo sapiens 290-298 12738634-8 2003 Interestingly, BCG-induced activation of NF-kappaB and the increased CD40L cell surface expression were blocked by the protein kinase C (PKC) inhibitors 1-[5-isoquinolinesulfonyl]-2-methylpiperazine and salicylate, both of which block phosphorylation of IkappaB. Salicylates 203-213 nuclear factor kappa B subunit 1 Homo sapiens 41-50 11826407-3 2002 Inhibition of nuclear factor kappaB (NF-kappaB) activation by aspirin and salicylate has been described in many cells. Salicylates 74-84 nuclear factor kappa B subunit 1 Homo sapiens 29-35 11826407-3 2002 Inhibition of nuclear factor kappaB (NF-kappaB) activation by aspirin and salicylate has been described in many cells. Salicylates 74-84 nuclear factor kappa B subunit 1 Homo sapiens 37-46 14993359-3 2002 For example, salicylates and glucocorticoids, two widely used anti-inflammatory drug classes, are now known to inhibit the activation of NF-kappa B, a transcription factor that regulates the inducible expression of a wide range of proinflammatory mediators. Salicylates 13-24 nuclear factor kappa B subunit 1 Homo sapiens 137-147 15672440-8 2005 Concomitant injections of antioxidants, however, such as 2,3-dihydroxybenzoic acid or salicylate (which prevent cell death induced by kanamycin), promoted the translocation of NF-kappaB into the nuclei of outer hair cells. Salicylates 86-96 nuclear factor kappa B subunit 1 Homo sapiens 176-185 11377405-3 2001 For ASA and salicylate, an NF-kappaB inhibitory effect at mM concentrations (pharmacological plasma concentrations reached in vivo) has been shown. Salicylates 12-22 nuclear factor kappa B subunit 1 Homo sapiens 27-36 10925251-7 2000 Moreover, salicylate blocked nuclear localization of NF-kappa B factors that bind to the NF-kappa B binding site in the Bcl-xL promoter, as well as the expression of Bcl-xL protein. Salicylates 10-20 nuclear factor kappa B subunit 1 Homo sapiens 53-63 10925251-7 2000 Moreover, salicylate blocked nuclear localization of NF-kappa B factors that bind to the NF-kappa B binding site in the Bcl-xL promoter, as well as the expression of Bcl-xL protein. Salicylates 10-20 nuclear factor kappa B subunit 1 Homo sapiens 89-99 10217529-7 1999 Both HTB and triflusal were more potent than aspirin or salicylate as inhibitors of the nuclear translocation of NF-kappaB. Salicylates 56-66 nuclear factor kappa B subunit 1 Homo sapiens 113-122 10217529-16 1999 These data indicate that the incorporation of a 4-trifluoromethyl group to the salicylate molecule strongly enhances its inhibitory effect on NF-kappaB activation, VCAM-1 mRNA expression and iNOS induction, irrespective of the presence of the acetyl moiety involved in the inhibition of cyclo-oxygenase. Salicylates 79-89 nuclear factor kappa B subunit 1 Homo sapiens 142-151 9817203-7 1998 Our results indicate that the anti-inflammatory properties of aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. Salicylates 74-84 nuclear factor kappa B subunit 1 Homo sapiens 181-190 9380028-10 1997 Salicylate prevented the activation of NF-kappaB by menadione, and under these conditions, salicylate potentiated the cytotoxicity of menadione or H2O2. Salicylates 0-10 nuclear factor kappa B subunit 1 Homo sapiens 39-48 9380028-10 1997 Salicylate prevented the activation of NF-kappaB by menadione, and under these conditions, salicylate potentiated the cytotoxicity of menadione or H2O2. Salicylates 91-101 nuclear factor kappa B subunit 1 Homo sapiens 39-48 9380028-15 1997 An increased level of GSH was observed after menadione pretreatment; this increase was blocked by salicylate, thereby linking the GSH increase to activation of NF-kappaB by menadione. Salicylates 98-108 nuclear factor kappa B subunit 1 Homo sapiens 160-169 10860828-0 2000 Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. Salicylates 128-139 nuclear factor kappa B subunit 1 Homo sapiens 97-106 10210643-0 1999 Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. Salicylates 0-11 nuclear factor kappa B subunit 1 Homo sapiens 20-29 9628380-3 1998 The authors measured expression of intercellular adhesion molecule-1 (ICAM-1), during hypoxia and normoxia and hypothesized that salicylate, which inhibits the nuclear factor-kappaB (NFkappaB), an hypoxia-dependent transmission factor, could reduce this expression. Salicylates 129-139 nuclear factor kappa B subunit 1 Homo sapiens 160-181 9628380-3 1998 The authors measured expression of intercellular adhesion molecule-1 (ICAM-1), during hypoxia and normoxia and hypothesized that salicylate, which inhibits the nuclear factor-kappaB (NFkappaB), an hypoxia-dependent transmission factor, could reduce this expression. Salicylates 129-139 nuclear factor kappa B subunit 1 Homo sapiens 183-191 9187256-5 1997 Recently, the identification of a cytokine-inducible isoform of COX, COX-2, has led to the suggestion that salicylate produces its anti-inflammatory actions by inhibiting COX-2 induction through actions on nuclear factor kappaB (NF-kappaB). Salicylates 107-117 nuclear factor kappa B subunit 1 Homo sapiens 221-227 9187256-5 1997 Recently, the identification of a cytokine-inducible isoform of COX, COX-2, has led to the suggestion that salicylate produces its anti-inflammatory actions by inhibiting COX-2 induction through actions on nuclear factor kappaB (NF-kappaB). Salicylates 107-117 nuclear factor kappa B subunit 1 Homo sapiens 229-238